Francesco Sabbatino Selected Research

Histocompatibility Antigens Class I

1/2021	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.
1/2021	Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors.
10/2020	Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
1/2020	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
7/2016	Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
2/2016	HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
1/2016	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
1/2013	Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesco Sabbatino Research Topics

Disease

28	Neoplasms (Cancer) 01/2022 - 01/2013
16	Melanoma (Melanoma, Malignant) 01/2022 - 07/2013
5	Cholangiocarcinoma 01/2020 - 12/2015
3	Adenocarcinoma 01/2021 - 01/2015
3	Disease Progression 01/2021 - 04/2014
2	COVID-19 07/2021 - 01/2021
2	Alcoholism (Alcohol Abuse) 11/2017 - 06/2014
2	Pancreatic Neoplasms (Pancreatic Cancer) 11/2017 - 01/2015
2	Carcinoma (Carcinomatosis) 01/2016 - 01/2014
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 03/2022
1	Colorectal Neoplasms (Colorectal Cancer) 02/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2021
1	Chondrosarcoma 01/2021
1	Chordoma 01/2021
1	Infections 01/2021
1	Basal Cell Carcinoma (Rodent Ulcer) 11/2018
1	Small Cell Carcinoma 11/2018
1	Skin Neoplasms (Skin Cancer) 11/2018
1	HIV Infections (HIV Infection) 01/2017
1	Persistent Infection 01/2017
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2016
1	Primitive Neuroectodermal Tumors (PNET) 12/2016
1	Neuroblastoma 08/2015
1	Pancreatic Fistula (Pancreatic Fistulas) 01/2015
1	Glioblastoma (Glioblastoma Multiforme) 11/2014
1	Residual Neoplasm 06/2014
1	Breast Neoplasms (Breast Cancer) 06/2014
1	Autoimmune Diseases (Autoimmune Disease) 01/2014
1	Uveitis 01/2014
1	Ovarian Neoplasms (Ovarian Cancer) 01/2014
1	Hepatitis 01/2014
1	Enterocolitis 01/2014
1	Dermatitis 01/2014
1	Hypophysitis 01/2014

Drug/Important Bio-Agent (IBA)

8	Monoclonal AntibodiesIBA 11/2021 - 01/2013
8	Histocompatibility Antigens Class IIBA 01/2021 - 01/2013
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
7	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
5	RNA (Ribonucleic Acid)IBA 01/2021 - 04/2014
4	Pharmaceutical PreparationsIBA 01/2022 - 06/2014
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 01/2013
4	Immune Checkpoint ProteinsIBA 01/2021 - 01/2013
4	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 11/2014
3	InterferonsIBA 11/2021 - 07/2013
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 01/2014
3	Peptides (Polypeptides)IBA 01/2021 - 07/2016
3	AlbuminsIBA 01/2016 - 12/2015
2	Biological ProductsIBA 02/2022 - 01/2021
2	B7-H1 AntigenIBA 11/2021 - 01/2021
2	NivolumabIBA 05/2021 - 11/2018
2	folfirinoxIBA 01/2021 - 01/2015
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 04/2014
2	AntigensIBA 01/2021 - 10/2020
2	ParaffinIBA 01/2021 - 12/2016
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2014
1	carboxyl radical (COO-)IBA 03/2022
1	TriazinesIBA 11/2021
1	tocilizumab (atlizumab)FDA Link 07/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	HLA-A Antigens (HLA-A)IBA 01/2021
1	BuffersIBA 01/2021
1	Leucovorin (Folinic Acid)FDA Link 01/2021
1	Ethanol (Ethyl Alcohol)IBA 01/2021
1	VemurafenibIBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Citric Acid (Citrate)FDA LinkGeneric 01/2021
1	LigandsIBA 01/2021
1	cobimetinibIBA 01/2021
1	Xylenes (Xylene)IBA 01/2021
1	VaccinesIBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	CalreticulinIBA 01/2019
1	Disulfiram (Antabuse)FDA Link 11/2017
1	Celecoxib (Celebrex)FDA Link 01/2017
1	Histones (Histone)IBA 12/2016
1	CytokinesIBA 07/2016
1	Proto-Oncogene Proteins B-rafIBA 02/2016
1	Complement System Proteins (Complement)IBA 08/2015
1	GD2 gangliosideIBA 08/2015
1	Topoisomerase I InhibitorsIBA 11/2014
1	Aldehyde DehydrogenaseIBA 06/2014
1	Growth Factor ReceptorsIBA 04/2014
1	sonidegibIBA 04/2014
1	PlatinumIBA 01/2014
1	EpitopesIBA 01/2014
1	Sunitinib (Sutent)FDA Link 01/2014
1	IpilimumabIBA 01/2014

Therapy/Procedure

18	Immunotherapy 01/2022 - 01/2013
14	Therapeutics 01/2022 - 12/2013
2	Neoadjuvant Therapy 01/2021 - 01/2015
2	Drug Therapy (Chemotherapy) 11/2017 - 01/2014
1	Operative Time 01/2015
1	Radiotherapy 06/2014